Strong Q1 sales of $137.3M showcase Madrigal Pharmaceuticals, Inc.'s Rezdiffra's growth in non-cirrhotic NASH. Click for my ...

The Sacramento-area restaurateur appeared in Sacramento Superior Court on Thursday morning for a 2024 domestic violence case.

Madrigal will study SYH2086 in combination with Rezdiffra for metabolic dysfunction-associated steatohepatitis, aiming for ...

CEO touts 'amazing' sales success of new drug, but firm's stock slumps Montco firm's shares soar on huge sales increase of ...

U.S. drugmaker Madrigal Pharmaceuticals has struck a licensing deal with CSPC Pharmaceutical Group that could be worth more than $2 billion for the Chinese company if it results in a new drug for a ...

The idea is that SYH2086 can be paired with Rezdiffra, a selective thyroid hormone receptor agonist that became the first FDA-approved drug for metabolic dysfunction-associated steatohepatitis (MASH) ...

Madrigal Pharmaceuticals (NASDAQ:MDGL) said it has signed a global licensing deal with CSPC Pharmaceutical for SYH2086, a new ...

Conshohocken, Pa. Friday, August 1, 2025, 15:00 Hrs [IST] ...

Madrigal Pharmaceuticals secures global rights to SYH2086, aiming to enhance MASH treatment with innovative combination ...

Madrigal (MDGL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Madrigal Pharmaceuticals said on Wednesday it has entered into a licensing agreement worth up to $2 billion with China's CSPC Pharmaceutical Group to develop an oral GLP-1 drug for a serious form of ...